Eli Lilly’s retatrutide weight loss trial achieved up to 30.3% body weight reduction, matching bariatric surgery. Phase 3 TRIUMPH-1 data, mechanism, and access analysis.
Evidence-based review of intermittent fasting for obesity, type 2 diabetes, CVD, NAFLD, neurodegeneration, and cancer. Safety, protocols, and who should avoid IF.
Evidence for lion’s mane (cognition), reishi (immune, cancer QoL), and chaga (antioxidants). Safety: bleeding risk, liver toxicity, kidney damage.
FDA approves Eli Lilly’s GLP-1 weight loss pill Foundayo. A once-daily oral drug that could transform obesity care. Read analysis.
